ADvantage Therapeutics develops therapies to treat neurodegenerative conditions focusing on Alzheimer’s Disease.
ADvantage Therapeutics has raised $2.5M in total funding. The most recent round was Grant. The last funding was announced in September 2025.
ADvantage Therapeutics's investors include National Institute on Aging.
ADvantage Therapeutics is headquartered in Miami, United States.
ADvantage Therapeutics develops therapies to treat neurodegenerative conditions focusing on Alzheimer’s Disease.
ADvantage Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ADvantage Therapeutics — Funding & Investors." VCBacked, September 26, 2025, https://www.vcbacked.co/company/advantage-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). ADvantage Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/advantage-therapeutics
{{cite web |title=ADvantage Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/advantage-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated